Brief: Phase 3 Clinical Trial Of Hansizhuang Plus Chemotherapy Meets Primary Endpoint In Neoadjuvant/Adjuvant Gastric Cancer, Greenlighting Early NDA Submission
09/10/2025 13:55
Oct 9 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK: PHASE 3 CLINICAL TRIAL OF HANSIZHUANG PLUS CHEMOTHERAPY MEETS PRIMARY ENDPOINT IN NEOADJUVANT/ADJUVANT GASTRIC CANCER, GREENLIGHTING EARLY NDA SUBMISSION Source text: ID:nPn29KFyDa Further company coverage: 2696.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln